BioPharmSignal logoBioPharmSignal

Biotech News

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook (OTLK)OutlookCommercial

Seasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industries Deep expertise spans commercial operations, capital markets, public company finance, and building scalable financial

Related news

OTLKOutlook2026-06-16 12:02 EST

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

OTLKOutlook2026-06-01 12:46 EST

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

HROWHarrow, Inc.2026-07-01 11:00 EST

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

HROWHarrow, Inc.2026-06-10 11:00 EST

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

LCTXLineage Cell Therapeutics2026-08-06 20:01 EST

Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

LENZLenz Therapeutics Inc2026-08-04 20:05 EST

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

LCTXLineage Cell Therapeutics2026-07-30 12:00 EST

Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

View all latest news

Outlook

Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...

Recent company news

OTLKOutlook2026-09-11 11:00 EST

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

OTLKOutlook2026-09-10 13:10 EST

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

OTLKOutlook2026-08-27 20:05 EST

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

OTLKOutlook2026-08-27 13:01 EST

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

OTLKOutlook2026-08-14 11:15 EST

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Stock data

Close
0.68 USD
Market cap
120.89M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States